Merit Medical Systems, Inc. (NASDAQ:MMSI) Director F. Ann Millner Sells 12,500 Shares

Merit Medical Systems, Inc. (NASDAQ:MMSIGet Free Report) Director F. Ann Millner sold 12,500 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the completion of the sale, the director now owns 32,391 shares of the company’s stock, valued at $3,289,306.05. The trade was a 27.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Merit Medical Systems Stock Performance

Shares of NASDAQ:MMSI opened at $103.94 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The business’s fifty day moving average price is $97.80 and its two-hundred day moving average price is $90.09. Merit Medical Systems, Inc. has a fifty-two week low of $65.46 and a fifty-two week high of $105.46. The stock has a market capitalization of $6.06 billion, a price-to-earnings ratio of 49.92, a price-to-earnings-growth ratio of 2.53 and a beta of 0.89.

Merit Medical Systems (NASDAQ:MMSIGet Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The firm had revenue of $339.85 million for the quarter, compared to analyst estimates of $334.60 million. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. As a group, analysts predict that Merit Medical Systems, Inc. will post 3.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors have recently bought and sold shares of the business. Opal Wealth Advisors LLC acquired a new stake in shares of Merit Medical Systems in the second quarter valued at $29,000. DekaBank Deutsche Girozentrale bought a new position in shares of Merit Medical Systems in the first quarter worth about $44,000. USA Financial Formulas acquired a new position in shares of Merit Medical Systems during the third quarter worth approximately $59,000. EntryPoint Capital LLC grew its stake in shares of Merit Medical Systems by 2,666.7% during the first quarter. EntryPoint Capital LLC now owns 913 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 880 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Merit Medical Systems by 142.3% in the second quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 488 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

MMSI has been the subject of a number of research analyst reports. Bank of America boosted their target price on shares of Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research report on Monday, September 16th. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. Wells Fargo & Company lifted their price target on Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a research report on Monday, September 16th. Needham & Company LLC reissued a “buy” rating and issued a $109.00 price objective on shares of Merit Medical Systems in a research report on Thursday, October 31st. Finally, Robert W. Baird boosted their target price on shares of Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $103.36.

Read Our Latest Analysis on Merit Medical Systems

About Merit Medical Systems

(Get Free Report)

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.

Read More

Insider Buying and Selling by Quarter for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.